CStone Presents the Latest Preclinical Findings of CS2009 (PD-1/VEGF/CTLA-4 trispecific antibody) at 2025 AACR
- On May 5, 2025, CStone Pharmaceuticals shared findings from early-stage studies of CS2009, a trispecific antibody targeting PD-1, VEGF, and CTLA-4, during the 2025 AACR Annual Meeting held in Suzhou, China.
- CStone developed CS2009 to combine blockade of PD-1, VEGFA, and CTLA-4, clinically validated immunotherapy targets known for synergistic anti-tumor effects and extended survival benefits.
- CS2009 enhances efficacy by targeting PD-1/CTLA-4 double-positive T cells and crosslinking VEGFA dimers, showing an up to 300-fold increase in checkpoint inhibitory activity in assays.
- Preclinical evaluations showed that CS2009 activates T-cells in a dose-dependent manner, has pharmacokinetic characteristics similar to monoclonal antibodies, is very well tolerated, and exhibited no adverse effects at doses up to 100 mg/kg in cynomolgus monkeys.
- The global phase I trial started in March 2025 in Australia and will expand to China and the US, supporting CS2009's potential as a next-generation immune-oncology backbone against solid tumors including NSCLC.
Insights by Ground AI
Does this summary seem wrong?
70 Articles
70 Articles
All
Left
8
Center
21
Right
4

+68 Reposted by 68 other sources
CStone Presents the Latest Preclinical Findings of CS2009 (PD-1/VEGF/CTLA-4 trispecific antibody) at 2025 AACR
SUZHOU, China, May 5, 2025 /PRNewswire/ -- CStone Pharmaceuticals ("CStone", HKEX: 2616), an innovation-driven biopharmaceutical company focused on anti-cancer therapies, announced today that a poster presentation of preclinical data of CS2009 (PD-1/VEGF/CTLA-4 trispecific antibody), a key asset in CStone Pipeline…
Coverage Details
Total News Sources70
Leaning Left8Leaning Right4Center21Last UpdatedBias Distribution64% Center
Bias Distribution
- 64% of the sources are Center
64% Center
L 24%
C 64%
12%
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage